EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank69
3Y CAGR-15.1%
5Y CAGR-2.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-15.1%/yr
Quarterly compound
5Y CAGR
-2.5%/yr
Recent deceleration
Percentile
P69
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 24.00% |
| Q3 2025 | -13.95% |
| Q2 2025 | -5.25% |
| Q1 2025 | 35.05% |
| Q4 2024 | 46.81% |
| Q3 2024 | -0.94% |
| Q2 2024 | -1.05% |
| Q1 2024 | 67.90% |
| Q4 2023 | 3.39% |
| Q3 2023 | 10.38% |
| Q2 2023 | 15.51% |
| Q1 2023 | -12.38% |
| Q4 2022 | 39.25% |
| Q3 2022 | -14.09% |
| Q2 2022 | 30.64% |
| Q1 2022 | 11.52% |
| Q4 2021 | 4.94% |
| Q3 2021 | 51.61% |
| Q2 2021 | 2.30% |
| Q1 2021 | 5.26% |
| Q4 2020 | 27.26% |
| Q3 2020 | 24.85% |
| Q2 2020 | -32.50% |
| Q1 2020 | 17.48% |
| Q4 2019 | 18.57% |
| Q3 2019 | -11.91% |
| Q2 2019 | 4.16% |
| Q1 2019 | -9.14% |
| Q4 2018 | -32.95% |
| Q3 2018 | 30.81% |
| Q2 2018 | 43.31% |
| Q1 2018 | -22.11% |
| Q4 2017 | 11.78% |
| Q3 2017 | -9.35% |
| Q2 2017 | 26.74% |
| Q1 2017 | 5.02% |
| Q4 2016 | -24.25% |
| Q3 2016 | 1.80% |
| Q2 2016 | 33.51% |
| Q1 2016 | -17.39% |